Related references
Note: Only part of the references are listed.Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort
Arturo Ciccullo et al.
VIRUSES-BASEL (2022)
Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens
Karam Mounzer et al.
Open Forum Infectious Diseases (2022)
Late cART Initiation Consistently Driven by Late HIV Presentation: A Multicenter Retrospective Cohort Study in Taiwan from 2009 to 2019
Chun-Yuan Lee et al.
INFECTIOUS DISEASES AND THERAPY (2022)
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort
Arturo Ciccullo et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2021)
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment
Ashima Pyngottu et al.
CLINICAL INFECTIOUS DISEASES (2021)
Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors
G. Schuettfort et al.
HIV MEDICINE (2021)
High prevalence of recreational and illicit drug use in German people living with HIV with a potential for drug-drug interactions with antiretroviral therapy
B. Funke et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2021)
Changing Pattern of Chemsex Drug Use Among Newly Diagnosed HIV-Positive Taiwanese from 2015 to 2020 in the Era of Treat-All Policy
Chun-Yuan Lee et al.
AIDS PATIENT CARE AND STDS (2021)
Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis
Anthony Allen Reeves et al.
SEXUALLY TRANSMITTED INFECTIONS (2021)
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV
Arturo Ciccullo et al.
EXPERT OPINION ON DRUG SAFETY (2021)
Cascade Analysis of Anonymous Voluntary HIV Counseling and Testing Among Patients with HIV Infection in Taiwan
Chun-Yuan Lee et al.
AIDS PATIENT CARE AND STDS (2020)
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Chloe Orkin et al.
Lancet HIV (2020)
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
Kimberly K. Scarsi et al.
DRUGS (2020)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings
Daniele Armenia et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Antiretroviral adherence and virologic suppression in partnered and unpartnered HIV-positive individuals in southern Brazil
Marineide Goncalves de Melo et al.
PLOS ONE (2019)
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Hans-Juergen Stellbrink et al.
LANCET HIV (2019)
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
David A. Wohl et al.
LANCET HIV (2019)
Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs
Nanina Anderegg et al.
CLINICAL INFECTIOUS DISEASES (2018)
Patient-Reported Symptoms Over 48Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine
David Wohl et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2018)
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
C. Hoffmann et al.
HIV MEDICINE (2017)
Tolerability of integrase inhibitors in a real-life setting
Judit Penafiel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel Gallant et al.
LANCET (2017)
Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up
Kuan-Yin Lin et al.
PLOS ONE (2017)
The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients
Hartmut B. Krentz et al.
AIDS PATIENT CARE AND STDS (2016)
Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy
S. Scott Sutton et al.
PHARMACOTHERAPY (2016)
Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis A Systematic Review and Meta-analysis
Olalekan A. Uthman et al.
ANNALS OF INTERNAL MEDICINE (2015)
Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review
Christian Manzardo et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2015)
Association of HLA-B*5701 Genotypes and Abacavir-Induced Hypersensitivity Reaction: A Systematic Review and Meta-Analysis
Wimonchat Tangamornsuksan et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2015)
Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV
Calvin J. Cohen et al.
BMJ OPEN (2013)
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
Sherene Min et al.
AIDS (2011)
Late presentation of HIV infection: a consensus definition
A. Antinori et al.
HIV MEDICINE (2011)
HLA-B*5701 screening for hypersensitivity to abacavir
Simon Mallal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan
Hsin-Yun Sun et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease
Christian Manzardo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Share Paper
